Ms. Xiao will oversee the Company’s Investment and Financing Strategy Department, with responsibilities encompassing the Finance Department, Internal Audit Department, and budget management. She will report directly to Dr. Wenzhi Tian, Chairman, Chief Executive Officer, and Chief Scientific Officer of ImmuneOnco.

Recognized for its outstanding innovative R&D capabilities and robust pipeline, this dual recognition not only highlights the industry's high affirmation of ImmuneOnco's technological innovation but also further solidifies the Company's leading position in the biopharmaceutical sector.

The data demonstrated that amulirafusp alfa achieved profound B-cell depletion while exhibiting an excellent safety and tolerability profile, alongside robust and durable clinical efficacy.

This marks the fourth consecutive year that IMM2510 has been featured at ASCO, the premier global oncology conference, further validating the robust global R&D capabilities and sustained potential of this blockbuster bispecific therapy.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Announces First Patient Enrolled in Phase II Randomized Controlled Study of IMM0306 for the Treatment of Systemic Lupus Erythematosus